🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Cancer (NSCLC) With Multiple Metastases

RecruitingPhase 2Ages 18 Years - 75 YearsAllXinqiao Hospital of Chongqing
NCT06953843 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study aims to conduct a prospective, multicenter, umbrella clinical study to compare the abscopal effects of different radiotherapy fractionation patterns combined with Benmelstobart, and to explore an efficient and low-toxic treatment strategy for non-small cell lung cancer (NSCLC) with multiple metastases. The main objective is to explore and compare the control rates of abscopal lesions in NSCLC patients with multiple metastases when different radiotherapy fractionation patterns are combined with Benmelstobart.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patient must meet all of the following inclusion criteria to be enrolled in this study: 1. Non-small cell lung cancer confirmed by pathological histology. 2. More than 3 metastatic lesions. 3. No brain metastases or stable lesions. 4. Negative for driver genes (including EGFR, ALK, ROS, BRAF, MET, RET). 5. Performance status (PS) score of 0-1, with an expected survival period of more than 3 months. 6. Age between 18 and 75 years old. 7. Assessment by PET-CT (including FDG and FMISO, not mandatory). 8. No contraindications to immunotherapy and radiotherapy. 9. Signed the informed consent form. Exclusion Criteria: * Patients with any of the following criteria are not eligible for enrollment in this study: 1. Those with severe dysfunction of important vital organs (heart, liver, kidney). 2. Those accompanied by other malignant tumors. 3. Uncontrolled heart diseases or myocardial infarction within the past 6 months. 4. Those with a history of mental illness. 5. Other situations in which the researcher deems it inappropriate for the subject to participate in the study.
💊

What it tests

  • Benmelstobart combined with chemotherapy
  • Benmelstobart combined with chemotherapy
  • Benmelstobart combined with chemotherapy
  • Benmelstobart combined with chemotherapy
  • Benmelstobart combined with chemotherapy
📍

Where

1 site
the second affiliated hospital of Army medical university
Chongqing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy